Mirxes Announces Successful Completion of HK$711 Million Placing to Accelerate Global Cancer Screening Expansion

On May 23, 2025, Mirxes successfully listed on the Main Board of the Hong Kong Stock Exchange, raising HKD 1.086 billion. Just eight months after its IPO, Mirxes completed a large-scale financing round, bringing the total funds raised to nearly HKD 2 billion. This not only reflects global investors' recognition of the company’s value but also provides substantial financial support for its technology research and development, commercialization efforts, and global business expansion, helping the company strengthen its competitive edge in the industry and steadily achieve its medium- and long-term development goals. According to the announcement, the proceeds from this placement will focus on Mirxes’ core strategic development directions, including investment and acquisition activities, continuous R&D upgrades for its product pipeline, accelerated advancement of its global commercialization strategy, and iterative optimization of its technological innovation platform.

Currently, the global cancer early screening track has entered a boom period of deep integration between capital and industry, with the industry's growth potential of over 100 billion continuously highlighted. By 2025, international medical and technology giants such as Samsung, Roche, and Abbott have strategically invested and made massive acquisitions to enter the track. Among them, Abbott acquired for $21 billion.ExactSciences`, setting a record as the largest M&A deal in the global medical device industry that year, fully demonstrating the core strategic value of the track.`

As the only listed early screening company in Asia, Mirxes, headquartered in Singapore, is an RNA biotechnology company deeply rooted in the Southeast Asian and East Asian markets. It is committed to developing and commercializing precise, non-invasive, and affordable early screening solutions for cancer and other diseases.Blood miRNA Detection. It is the world's first and only company to receive regulatory approval for an IVD product for molecular gastric cancer screening. In addition to its core gastric cancer screening product, the company’s early screening products for single-cancer types such as lung cancer, colorectal cancer, and breast cancer are all in orderly and active stages of development, with the colorectal cancer screening product expected to launch soon. At the same time, the company has proactively laid out a strategic plan for CADENCE multi-cancer screening.Multi-omics TestingProject, comprehensively covering the diversified market demands in the field of early cancer screening. Core productsMicroGuard®Successfully Obtained the Third-Class Medical Device Registration Certificate from the China National Medical Products Administration, a milestone achievement that fully demonstrates the company's technical approach and commercial logic are steadily being realized.

It is reported that the HKD 711 million raised from this placement will focus on the core strategic development direction of Mirxes, including investment and mergers & acquisitions, continuous R&D upgrades for the product pipeline, acceleration of global commercialization efforts, as well as iterative optimization of the technology innovation platform.

Recently, Mirxes issued an announcement, withXtalPiOfficially signed a Memorandum of Understanding for strategic cooperation, targeting high-incidence cancer types in Asia, especially gastrointestinal cancers, as the key area. The collaboration aims to jointly build an AI-powered "integrated diagnosis and treatment" innovative research and industrialization platform. This partnership will leverage Mirxes' leading advantages in Asian population cancer data and early detection, deeply integrating with XtalPi’s AI-driven drug R&D capabilities to establish a closed-loop solution from early detection to precise intervention. With a dual-driven model of data + AI, this initiative sets a new benchmark for the innovative development of the global precision medicine industry while introducing new business growth opportunities for the companies involved.

Currently, Hong Kong's capital market is continuously strengthening IPO supervision. In December 2025, the Hong Kong Securities and Futures Commission (SFC) and the Hong Kong Stock Exchange jointly sent a letter to sponsors, directly addressing prominent issues such as the quality of listing application documents and compliance procedures, signaling a clear trend of stricter listing reviews and a focus on quality improvement and efficiency enhancement. Against this backdrop, Mirxes, with its globally exclusive molecular early gastric cancer screening approval qualifications, clear technological barriers, rapidly commercialized achievements, and various milestones that continue to be realized post-listing, has become a rare target in the Hong Kong stock market’s biopharmaceutical sector, combining compliance and growth potential.

The global track of early cancer screening and precision medicine continues to heat up, with broad industry development prospects and increasing popularity.Mirxes MiRui has built an unsurpassable technical barrier with its globally exclusive molecular gastric cancer screening technology qualification, a mature RNA detection technology platform, and a continuously iterated product pipeline, earning high recognition from global capital.